Skye Bioscience (FRA:09R) Total Equity: €7.80 Mil (As of Mar. 2026)


FRA:09R Skye Bioscience Inc FRA:09R
12 GF Score
Price €0.56
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience Total Equity?

Skye Bioscience FRA:09R -15.91% 12 Total Equity is €7.80 Mil as of Mar. 2026. GuruFocus rates FRA:09R with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Skye Bioscience's total equity for the quarter that ended in Mar. 2026 was €7.80 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Skye Bioscience Total Equity Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Total Equity Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.19 -2.84 -1.96 65.09 17.10

Skye Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.81 37.87 27.98 17.10 7.80
FRA:09R
12GF Score
Skye Bioscience Inc FRA:09R
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Skye Bioscience's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=24.18-7.079
=17.10

Skye Bioscience's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=16.796-9
=7.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €7.80 Mil mean?
Skye Bioscience (FRA:09R) has a Total Equity of €7.80 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Skye Bioscience and its competitors.
Is Skye Bioscience's Total Equity too high?
Skye Bioscience's current Total Equity is €7.80 Mil. Overall, Skye Bioscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Total Equity compare to PLRZ and NEUP?
Skye Bioscience's Total Equity of €7.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Skye Bioscience and its competitors. Skye Bioscience's current Total Equity is €7.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Total Equity of €7.80 Mil. The current Total Equity is €7.80 Mil. Skye Bioscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Total Equity is €7.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
12GF Score

Get the complete analysis for FRA:09R

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.56
Price